182 related articles for article (PubMed ID: 34796992)
41. Detection of blood Gb3 deposits as a new tool for diagnosis and therapy monitoring in patients with classic Fabry disease.
Üçeyler N; Böttger J; Henkel L; Langjahr M; Mayer C; Nordbeck P; Wanner C; Sommer C
J Intern Med; 2018 Oct; 284(4):427-438. PubMed ID: 29974530
[TBL] [Abstract][Full Text] [Related]
42. Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease.
Porto C; Pisani A; Rosa M; Acampora E; Avolio V; Tuzzi MR; Visciano B; Gagliardo C; Materazzi S; la Marca G; Andria G; Parenti G
J Inherit Metab Dis; 2012 May; 35(3):513-20. PubMed ID: 22187137
[TBL] [Abstract][Full Text] [Related]
43. A classical phenotype of Anderson-Fabry disease in a female patient with intronic mutations of the GLA gene: a case report.
Pisani A; Imbriaco M; Zizzo C; Albeggiani G; Colomba P; Alessandro R; Iemolo F; Duro G
BMC Cardiovasc Disord; 2012 Jun; 12():39. PubMed ID: 22682330
[TBL] [Abstract][Full Text] [Related]
44. Screening for Fabry Disease by Urinary Globotriaosylceramide Isoforms Measurement in Patients with Left Ventricular Hypertrophy.
Gaggl M; Lajic N; Heinze G; Voigtländer T; Sunder-Plassmann R; Paschke E; Fauler G; Sunder-Plassmann G; Mundigler G
Int J Med Sci; 2016; 13(5):340-6. PubMed ID: 27226774
[TBL] [Abstract][Full Text] [Related]
45. [Fabry Disease: Pathogenesis, Clinical Symptoms, and Treatment with Enzyme Replacement Therapy].
Sawai S
Brain Nerve; 2015 Sep; 67(9):1099-108. PubMed ID: 26329150
[TBL] [Abstract][Full Text] [Related]
46. Globotriaosylsphingosine (Lyso-Gb
Alharbi FJ; Baig S; Auray-Blais C; Boutin M; Ward DG; Wheeldon N; Steed R; Dawson C; Hughes D; Geberhiwot T
J Inherit Metab Dis; 2018 Mar; 41(2):239-247. PubMed ID: 29294190
[TBL] [Abstract][Full Text] [Related]
47. Plasma Globotriaosylsphingosine Level as a Primary Screening Target for Fabry Disease in Patients With Left Ventricular Hypertrophy.
Yamashita S; Saotome M; Satoh H; Kajihara J; Mochizuki Y; Mizuno K; Nobuhara M; Miyajima K; Kumazawa A; Tominaga H; Takase H; Tawarahara K; Wakahara N; Matsunaga M; Wakabayashi Y; Matsumoto Y; Terada H; Sano M; Ohtani H; Urushida T; Hayashi H; Ishii S; Maruyama H; Maekawa Y
Circ J; 2019 Aug; 83(9):1901-1907. PubMed ID: 31308318
[TBL] [Abstract][Full Text] [Related]
48. Identification of a Missense Mutation in the α-galactosidase A Gene in a Chinese Family with Fabry Disease.
Wu Y; Xia H; Yuan J; Xu H; Deng X; Liu J; Zhang H; Deng H
Curr Genomics; 2018 Jan; 19(1):70-75. PubMed ID: 29491734
[TBL] [Abstract][Full Text] [Related]
49. Enzyme Replacement Therapy Clears Gb3 Deposits from a Podocyte Cell Culture Model of Fabry Disease but Fails to Restore Altered Cellular Signaling.
Braun F; Blomberg L; Brodesser S; Liebau MC; Schermer B; Benzing T; Kurschat CE
Cell Physiol Biochem; 2019; 52(5):1139-1150. PubMed ID: 30990584
[TBL] [Abstract][Full Text] [Related]
50. Narrative review: Fabry disease.
Clarke JT
Ann Intern Med; 2007 Mar; 146(6):425-33. PubMed ID: 17371887
[TBL] [Abstract][Full Text] [Related]
51. Parkinson's Disease and Fabry Disease: Clinical, Biochemical and Neuroimaging Analysis of Three Pedigrees.
Gago MF; Azevedo O; Guimarães A; Teresa Vide A; Lamas NJ; Oliveira TG; Gaspar P; Bicho E; Miltenberger-Miltenyi G; Ferreira J; Sousa N
J Parkinsons Dis; 2020; 10(1):141-152. PubMed ID: 31594250
[TBL] [Abstract][Full Text] [Related]
52. A Novel Missense GLA Mutation (p.G35V) Detected in Hemodialysis Screening Leads to Severe Systemic Manifestations of Fabry Disease in Men and Women.
Veloso VSP; Ataides TL; Canziani MEF; Veloso MP; da Silva NA; Barreto DV; Pereira ERS; de Moura LAR; Barreto FC
Nephron; 2018; 138(2):147-156. PubMed ID: 28892806
[TBL] [Abstract][Full Text] [Related]
53. Proposed high-risk screening protocol for Fabry disease in patients with renal and vascular disease.
Auray-Blais C; Millington DS; Young SP; Clarke JT; Schiffmann R
J Inherit Metab Dis; 2009 Apr; 32(2):303-8. PubMed ID: 19169844
[TBL] [Abstract][Full Text] [Related]
54. Fabry Disease with Pacemaker Implantation as the Initial Event.
Kato Y; Ishikawa A; Aoki S; Sato H; Ojima Y; Kagaya S; Nagasawa T
Intern Med; 2019 Oct; 58(20):2993-3000. PubMed ID: 31243236
[TBL] [Abstract][Full Text] [Related]
55. Painful fingers, heat intolerance, and telangiectases of the ear: easily ignored childhood signs of Fabry disease.
Shelley ED; Shelley WB; Kurczynski TW
Pediatr Dermatol; 1995 Sep; 12(3):215-9. PubMed ID: 7501549
[TBL] [Abstract][Full Text] [Related]
56. Results of Fabry Disease Screening in Male Pre-End Stage Renal Disease Patients with Unknown Etiology Found Through the Platform of a Chronic Kidney Disease Education Program in a Northern Taiwan Medical Center.
Lin CJ; Chien YH; Lai TS; Shih HM; Chen YC; Pan CF; Chen HH; Hwu WL; Wu CJ
Kidney Blood Press Res; 2018; 43(5):1636-1645. PubMed ID: 30380558
[TBL] [Abstract][Full Text] [Related]
57. Biomarkers for Diagnosing and Staging of Fabry Disease.
Kramer J; Weidemann F
Curr Med Chem; 2018; 25(13):1530-1537. PubMed ID: 28618999
[TBL] [Abstract][Full Text] [Related]
58. Renal involvement in Fabry disease.
Abensur H; Reis MA
J Bras Nefrol; 2016 Jun; 38(2):245-54. PubMed ID: 27438980
[TBL] [Abstract][Full Text] [Related]
59. Fabry disease in children: agalsidase-beta enzyme replacement therapy.
Borgwardt L; Feldt-Rasmussen U; Rasmussen AK; Ballegaard M; Meldgaard Lund A
Clin Genet; 2013 May; 83(5):432-8. PubMed ID: 22880956
[TBL] [Abstract][Full Text] [Related]
60. Angiokeratoma corporis diffusum with severe acroparesthesia, an endothelial abnormality, and inconspicuous genetic findings.
Harzer K; Beck-Wödl S; Haack TB
J Cutan Pathol; 2022 Mar; 49(3):293-298. PubMed ID: 34672003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
